^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Glioblastoma
    Drug:Kinenza (enzastaurin) (PI3K inhibitor, AKT inhibitor, PKCĪ² inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Denovo Biopharma
    Title:

    FDA Grants Fast Track Designation For DB102 in Patients with Newly-Diagnosed Glioblastoma (GBM)

    Published date:
    07/17/2020
    Excerpt:
    Denovo Biopharma LLC...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DB102 (enzastaurin) being developed for the potential treatment of patients with newly-diagnosed glioblastoma.